MARKET

JAGX

JAGX

Jaguar Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6393
-0.0900
-12.34%
Pre Market: 0.6400 +0.0007 +0.11% 05:05 08/13 EDT
OPEN
0.7300
PREV CLOSE
0.7293
HIGH
0.7500
LOW
0.6220
VOLUME
6.28M
TURNOVER
--
52 WEEK HIGH
1.655
52 WEEK LOW
0.3507
MARKET CAP
20.58M
P/E (TTM)
-0.0348
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average JAGX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.

EPS

JAGX News

More
5 Value Stocks In The Healthcare Sector
Benzinga · 08/03 18:14
Jaguar Health Subsidiary Receiving Preclinical Services From The National Institute Of Allergy And Infectious Diseases For New Preclinical Study Initiated July 21, 2020 For Lechlemer Plant-based Drug Candidate For Cholera
SAN FRANCISCO, CA / ACCESSWIRE / July 22, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the 28-day preclinical toxicology and safety study in rats began
Benzinga · 07/22 12:32
FDA Invites Jaguar Health To Expedite Submission of Regulatory Filing For Approval For Canalevia To treat Chemotherapy-Induced Diarrhea In Dogs
Benzinga · 07/20 12:34
Jaguar Health completes IND filing for Mytesi for cancer therapy‑related diarrhea
Seeking Alpha - Article · 07/06 12:56
Jaguar Health Subsidiary Napo Pharmaceuticals Completes Filing Of Investigational New Drug Application For Cromfelemer For Symptomatic Relief Of Cancer Therapy-Related Diarrhea
Benzinga · 07/06 12:33
Jaguar Health Submits Final Major Regulatory Filing For Approval Of Canalevia To Treat Exercise-Induced Diarrhea In Dogs
Benzinga · 07/02 12:33
Bet on 4 Stocks With Rising P/E to Beat Market Blues
Zacks · 06/25 11:55
Jaguar Health Announces Preclinical Study Demonstrating Symptomatic Relief of Diarrhea in Dogs Receiving Neratinib in Combination with Crofelemer
Benzinga · 06/23 12:36

Industry

Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
+1.79%

Hot Stocks

Symbol
Price
%Change

About JAGX

Jaguar Health, Inc. is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.
More

Webull offers kinds of Jaguar Health Inc stock information, including NASDAQ:JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.